Directorate of Research, Studies and Documentation, National Public Health Organization, Athens, Greece.
Second Department of Internal Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Vaccine. 2021 Nov 26;39(48):7021-7027. doi: 10.1016/j.vaccine.2021.10.054. Epub 2021 Oct 30.
Healthcare personnel (HCP) are prioritized for coronavirus disease 2019 (COVID-19) vaccination to protect them and non-disruptive provision of healthcare services. We assessed the impact of the Pfizer-BioNTech vaccine on morbidity and absenteeism among HCP.
We studied 7445 HCP in five tertiary-care hospitals in Greece from November 15, 2020 through April 18, 2021.
A total of 910 episodes of absenteeism and 9695 days of absence were recorded during the entire study period. Starting from January 4, 2021, 4823/7445 HCP (64.8%) were fully or partially vaccinated. Overall, 535 episodes of absenteeism occurred from January 4, 2021 through April 18, 2021, including 309 (57.76%) episodes among 2622 unvaccinated HCP and 226 (42.24%) episodes among 4823 vaccinated HCP (11.8 versus 4.7 episodes of absenteeism per 100 HCP, respectively; p-value < 0.001). The mean duration of absenteeism was 11.9 days among unvaccinated HCP compared with 6.9 days among vaccinated HCP (p-value < 0.001). Unvaccinated HCP more frequently developed acute respiratory infection, influenza-like illness, and COVID-19 (p-values < 0.001 for all comparisons). Vaccine effectiveness for fully vaccinated HCP was estimated at 94.16% [confidence interval (CI): 88.50%-98.05%) against COVID-19, 83.62% (CI: 73.36%-90.38%) against SARS-CoV-2 infection (asymptomatic or COVID-19), and 66.42% (CI: 56.86%-74.15%) against absenteeism.
The COVID-19 pandemic had a considerable impact on healthcare workforce. The Pfizer-BioNTech vaccine significantly reduced morbidity, COVID-19, absenteeism and duration of absenteeism among HCP during a period of high SARS-CoV-2 circulation in the community. It is expected that HCP vaccination will protect them and healthcare services and contain healthcare costs.
将新冠病毒疾病 2019（COVID-19）疫苗接种给医疗保健人员（HCP）以保护他们和医疗服务的连续性。我们评估了辉瑞-生物技术公司疫苗对 HCP 发病率和旷工的影响。
我们研究了 2020 年 11 月 15 日至 2021 年 4 月 18 日期间希腊五所三级保健医院的 7445 名 HCP。
整个研究期间共记录了 910 例旷工和 9695 天缺勤。从 2021 年 1 月 4 日开始，4823/7445 HCP（64.8%）已完全或部分接种疫苗。总体而言，从 2021 年 1 月 4 日至 2021 年 4 月 18 日期间发生了 535 例旷工，其中包括 309 例（57.76%）在未接种疫苗的 2622 名 HCP 中，226 例（42.24%）在 4823 名接种疫苗的 HCP 中（每 100 名 HCP 分别发生 11.8 例和 4.7 例旷工；p 值均<0.001）。未接种疫苗的 HCP 旷工的平均持续时间为 11.9 天，而接种疫苗的 HCP 为 6.9 天（p 值均<0.001）。未接种疫苗的 HCP 更频繁地发生急性呼吸道感染、流感样疾病和 COVID-19（所有比较的 p 值均<0.001）。完全接种疫苗的 HCP 的疫苗有效性估计为 94.16%（置信区间[CI]：88.50%-98.05%），对 COVID-19 为 83.62%（CI：73.36%-90.38%），对 SARS-CoV-2 感染（无症状或 COVID-19）为 66.42%（CI：56.86%-74.15%），对旷工为 66.42%（CI：56.86%-74.15%）。
COVID-19 大流行对医疗保健人员产生了重大影响。在社区中 SARS-CoV-2 传播率高的情况下，辉瑞-生物技术公司疫苗显著降低了 HCP 的发病率、COVID-19、旷工和旷工时间。预计 HCP 接种疫苗将保护他们和医疗服务并控制医疗保健成本。
